Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:ANVSNASDAQ:ELEVNASDAQ:MBIONASDAQ:MURA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANVSAnnovis Bio$1.24-1.6%$1.72$1.11▼$20.00$17.65M1.51766,315 shs73,582 shsELEVElevation Oncology$0.39+16.7%$0.42$0.22▼$4.49$22.86M1.651.37 million shs2.68 million shsMBIOMustang Bio$1.33-0.7%$1.79$1.15▼$65.00$4.40M2.14248,757 shs32,618 shsMURAMural Oncology$2.70+11.6%$2.89$0.95▼$4.74$46.52M5.281.28 million shs5.74 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANVSAnnovis Bio-1.20%-2.52%-30.73%-75.30%-86.33%ELEVElevation Oncology+16.72%+42.96%-19.83%-45.73%-90.68%MBIOMustang Bio-0.75%-0.75%-6.99%-76.04%-93.07%MURAMural Oncology+11.57%+171.30%-36.17%-32.50%-28.19%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationANVSAnnovis Bio1.4889 of 5 stars3.51.00.00.00.61.70.6ELEVElevation Oncology2.6438 of 5 stars4.24.00.00.00.01.70.6MBIOMustang Bio1.7118 of 5 stars3.53.00.00.01.10.00.6MURAMural Oncology2.6043 of 5 stars3.33.00.00.02.21.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANVSAnnovis Bio 3.00Buy$37.002,883.87% UpsideELEVElevation Oncology 2.30Hold$3.39777.13% UpsideMBIOMustang Bio 3.00Buy$100.007,418.80% UpsideMURAMural Oncology 2.60Moderate Buy$13.00381.48% UpsideCurrent Analyst Ratings BreakdownLatest MBIO, MURA, ANVS, and ELEV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/26/2025MURAMural OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$18.00 ➝ $6.003/25/2025MURAMural OncologyMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight3/25/2025MURAMural OncologyRaymond JamesSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$18.003/25/2025MURAMural OncologyJones TradingSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Hold3/24/2025ELEVElevation OncologyStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$5.00 ➝ $1.003/21/2025ELEVElevation OncologyCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeMarket Perform3/21/2025ELEVElevation OncologyLeerink PartnersSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$9.00 ➝ $1.003/21/2025ELEVElevation OncologyCitizens JmpSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOutperform ➝ Market Perform3/21/2025ELEVElevation OncologyPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Neutral$10.00 ➝ $0.703/21/2025ELEVElevation OncologyHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$6.00 ➝ $1.003/20/2025ELEVElevation OncologyWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold(Data available from 4/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANVSAnnovis BioN/AN/AN/AN/A($0.73) per shareN/AELEVElevation OncologyN/AN/AN/AN/A$1.29 per shareN/AMBIOMustang BioN/AN/AN/AN/A$0.67 per shareN/AMURAMural OncologyN/AN/AN/AN/A$15.81 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANVSAnnovis Bio-$56.20M-$2.56N/AN/AN/AN/AN/A-311.00%5/12/2025 (Estimated)ELEVElevation Oncology-$45.70M-$0.81N/AN/AN/AN/A-59.73%-40.05%5/1/2025 (Estimated)MBIOMustang Bio-$51.60M-$78.00N/AN/AN/AN/AN/A-172.89%5/13/2025 (Estimated)MURAMural Oncology-$207.45M-$7.58N/AN/AN/AN/A-70.10%-61.30%5/13/2025 (Estimated)Latest MBIO, MURA, ANVS, and ELEV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025N/AMURAMural Oncology-$1.68N/AN/AN/AN/AN/A5/12/2025Q1 2025ANVSAnnovis Bio-$0.47N/AN/AN/AN/AN/A5/1/2025Q1 2025ELEVElevation Oncology-$0.20N/AN/AN/AN/AN/A3/21/2025Q4 2024ANVSAnnovis Bio-$0.38-$0.43-$0.05-$0.43N/AN/A3/11/2025Q4MURAMural Oncology-$1.96-$2.01-$0.05-$2.01N/AN/A3/6/2025Q4 2024ELEVElevation Oncology-$0.22-$0.18+$0.04-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthANVSAnnovis BioN/AN/AN/AN/AN/AELEVElevation OncologyN/AN/AN/AN/AN/AMBIOMustang BioN/AN/AN/AN/AN/AMURAMural OncologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANVSAnnovis BioN/A2.662.66ELEVElevation Oncology0.4517.7717.77MBIOMustang BioN/A0.400.40MURAMural OncologyN/A7.387.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANVSAnnovis Bio15.83%ELEVElevation Oncology83.70%MBIOMustang Bio9.95%MURAMural Oncology80.21%Insider OwnershipCompanyInsider OwnershipANVSAnnovis Bio32.30%ELEVElevation Oncology8.10%MBIOMustang Bio0.21%MURAMural Oncology0.06%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANVSAnnovis Bio314.24 million9.64 millionOptionableELEVElevation Oncology4059.22 million54.33 millionOptionableMBIOMustang Bio1003.31 million952,000Not OptionableMURAMural Oncology11917.23 million17.01 millionOptionableMBIO, MURA, ANVS, and ELEV HeadlinesRecent News About These CompaniesMass. biotech company cuts 90% of workforceApril 17 at 4:03 PM | msn.comForm 8.3 - The Vanguard Group, Inc.: Mural Oncology plcApril 17 at 10:55 AM | markets.businessinsider.comMural Oncology to discontinue nemvaleukin development, reduce staff by 90%April 16 at 1:11 PM | markets.businessinsider.comMURA Soars as it Explores Strategic Options Post Cancer Study FailuresApril 16 at 10:50 AM | zacks.comStrategic rethink as second Mural trial hits a wallApril 16 at 8:08 AM | thepharmaletter.comMural shuts down lead programme and slashes 90% of staffApril 16 at 8:08 AM | finance.yahoo.comBiotech Stock Mural Oncology (Nasdaq: MURA) Makes NASDAQ Top Gainer List on NewsApril 15 at 5:54 PM | investorideas.comBiotech Company Sees Stock Boost Following Major Strategy ShiftApril 15 at 5:54 PM | msn.comMural Oncology to Explore Options, Cut 90% of WorkforceApril 15 at 5:54 PM | marketwatch.comMural Oncology cuts 90% of staff, pulls plug on cancer drugApril 15 at 5:54 PM | bizjournals.comMural Oncology Shares Surge As Company Explores Strategic Alternatives: What's Going On?April 15 at 5:54 PM | benzinga.comMural risks going to the wall as IL-2 flop triggers 90% staff reduction, hunt for strategic alternativesApril 15 at 5:54 PM | fiercebiotech.comMural Oncology Announces Plans to Explore Strategic AlternativesApril 15 at 8:00 AM | globenewswire.comMural Oncology plc Ordinary SharesApril 12, 2025 | fxempire.comDevelopment of Nemvaleukin for Platinum-Resistant Ovarian Cancer HaltedApril 3, 2025 | curetoday.comCity of Indio creates new mural in honor of young local who battled cancerApril 2, 2025 | kesq.comMural Oncology: Phase 3 Clinical Trial Setback Undermines Company's Future ProspectsMarch 28, 2025 | seekingalpha.comNemvaleukin Lacks OS Benefit Over Chemo in Platinum-Resistant Ovarian CancerMarch 27, 2025 | oncnursingnews.comPetri Dish: Late-stage cancer trial halt; Dyne names CFOMarch 27, 2025 | bizjournals.comMural Oncology price target lowered to $6 from $18 at H.C. WainwrightMarch 27, 2025 | markets.businessinsider.comMural Oncology (NASDAQ:MURA) Receives Hold Rating from Jones TradingMarch 26, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMBIO, MURA, ANVS, and ELEV Company DescriptionsAnnovis Bio NYSE:ANVS$1.24 -0.02 (-1.59%) Closing price 04/17/2025 03:58 PM EasternExtended Trading$1.23 -0.01 (-1.21%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.Elevation Oncology NASDAQ:ELEV$0.39 +0.06 (+16.72%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$0.38 -0.01 (-1.30%) As of 04/17/2025 05:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Elevation Oncology, Inc., an oncology company, focuses on the discovery and development of cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs. The company's lead candidate is EO-3021, an antibody-drug conjugate designed to target Claudin 18.2, a clinically validated molecular target. Its EO-3021 selectively delivers a cytotoxic payload directly to cancer cells expressing Claudin 18.2. Elevation Oncology, Inc. has a license agreement with CSPC Megalith Biopharmaceutical Co., Ltd. to develop and commercialize EO-3021. The company was formerly known as 14ner Oncology, Inc. and changed its name to Elevation Oncology, Inc. in February 2020. The company was incorporated in 2019 and is based in Boston, Massachusetts.Mustang Bio NASDAQ:MBIO$1.33 -0.01 (-0.75%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$1.31 -0.02 (-1.50%) As of 04/17/2025 06:12 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment. The company also develops MB-106 CAR T cell program for B cell non-hodgkin lymphoma and chronic lymphocytic leukemia; MB-101 CAR T cell program for glioblastoma; MB-108, a next-generation oncolytic herpes simplex virus. It has license agreements with Nationwide Children's Hospital, CSL Behring; Mayo Clinic; Leiden University Medical Centre; SIRION Biotech GmbH. The company was incorporated in 2015 and is headquartered in Worcester, Massachusetts.Mural Oncology NASDAQ:MURA$2.70 +0.28 (+11.57%) Closing price 04/17/2025 04:00 PM EasternExtended Trading$2.69 -0.01 (-0.37%) As of 04/17/2025 06:24 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops nemvaleukin to treat cutaneous melanoma and advanced solid tumors. The company is also developing engineered interleukin-18 and tumor-targeted interleukin-12 programs. Mural Oncology plc was incorporated in 2017 and is based in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Archer Aviation Unveils NYC Network Ahead of Key Earnings Report Joby Aviation Stock Presents an Opportunity in the Turbulence Tariff Exemptions Set the Stage for a Taiwan Semiconductor Rally Tariff-Resistant Kinder Morgan Is a Good Buy in 2025 Rocket Lab's Growth Potential Gains Altitude on Defense News Broadcom’s Apple Relationship: AI Opportunity Meets Tariff Risk 3 Mid-Cap to Mega-Cap Stocks Have Announced Significant Buybacks Tariff-Resistant Abbott Laboratories on Track for New Highs Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
